VP, Global Head Regulatory Affairs, Vaccines & Immune Therapies
AstraZeneca
Amy Scott-Billman
VP & Global Head Regulatory Affairs, Vaccines & Immune Therapies
AstraZeneca
Amy joined AstraZeneca in June of this year and is VP & Global Head of Regulatory Affairs for Vaccines and Immune Therapies, a growing business unit at AZ.
Prior AZ, Amy spent >26 years at GSK in many capacities, including Corporate QA/Compliance and 24 years in escalating leadership roles in Regulatory Affairs for GSK’s Vaccines Division. Amy was a leader in the US region; built a global team from ground up for GSK’s Immunotherapeutics Business Unit and finally served as Global Head of Regulatory for Vaccines, leading all regulatory functions and then Global Head of the Vaccines.
During her career, Amy has served on countless regulatory matrix teams developing regulatory strategy, submissions and policy; served in governance; contributed to copious due diligence assessments; sponsored various innovation, process improvement and simplification efforts; served as Executive Sponsor for outsourcing partners and as an Inclusion & Diversity Sponsor. Leading global teams, responsible for vaccine development and commercialization, Amy personally drove or supported nearly every vaccine in the GSK portfolio; she has broad experience with global regulators and has had extensive experience in organizational and change management including helping to lead the integration of other companies into GSK.
Prior to GSK, Amy spent nearly 9 years at the USFDA Center for Biologics in applied research, as a reviewer, as an inspector and as a senior level policy maker. Amy is passionate about public health and about coaching and developing people, building high performing teams and creating community and culture designed to inspire and enable focus on driving the business and bringing medicines and vaccines with a patient first ambition.
Amy has a BS in Microbiology from The Pennsylvania State University and an MS in Biotechnology from The Johns Hopkins University.
Disclosure information not submitted.
Monday, September 12, 2022
9:45 AM – 11:00 AM MST